PRODIGY STUDY
PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY
PRODIGY is a Medtronic-sponsored, prospective, multi-center, international cohort study to identify patients at risk of opioid-induced respiratory depression (OIRD), a potentially life-threatening form of respiratory compromise. The PRODIGY study found a 46 percent incidence of respiratory depression in patients on the GCF receiving parenteral opioids.1
PRODIGY STUDY FACT SHEET
PRODIGY STUDY INFOGRAPHIC
PRODIGY STUDY
FAQs
Click here for more information about the PRODIGY study.
PRODIGY RISK PREDICTION TOOL INTERACTIVE PDF

Until now, no standardized tool has been available to assess risk of developing respiratory depression (RD), a form of respiratory compromise. The PRODIGY Risk Prediction Tool is an easy-to-use tool that helps identify which patients would benefit most from continuous monitoring.

Sign up to receive more information about the PRODIGY study:
Watch a video from study investigators about the importance of the PRODIGY study.



1.    Khanna AK, Bergese S, Jungquist CR, et al. Prediction of opioid-induced respiratory depression on inpatient wards using continuous capnography and oximetry: an international prospective, observational trial. Anesth Analg. In press 2020.